Zobrazeno 1 - 10
of 99
pro vyhledávání: '"J. Dorer"'
Autor:
Ha-Yeun Chung, Daniel C Hupe, Gordon P Otto, Marcel Sprenger, Alexander C Bunck, Michael J Dorer, Clemens L Bockmeyer, Hans-Peter Deigner, Markus H Gräler, Ralf A Claus
Publikováno v:
Molecular Medicine, Vol 22, Iss 1, Pp 412-423 (2016)
Abstract The pathophysiology of sepsis involves activation of acid sphingomyelinase (SMPD1) with subsequent generation of the bioactive mediator ceramide. We herein evaluate the hypothesis that the enzyme exerts biological effects in endothelial stre
Externí odkaz:
https://doaj.org/article/334c1b6047c34ed2ada0a927a7365093
Autor:
Daryl Sonnichsen, Michael J. Hanley, Meera Tugnait, Karthik Venkatakrishnan, David J. Dorer, Neeraj Gupta, Narayana I. Narasimhan, David Kerstein
Publikováno v:
Clinical Pharmacology in Drug Development
In vitro data support involvement of cytochrome P450 (CYP)2C8 and CYP3A4 in the metabolism of the anaplastic lymphoma kinase inhibitor brigatinib. A 3‐arm, open‐label, randomized, single‐dose, fixed‐sequence crossover study was conducted to c
Autor:
M. Bustin, Takashi Furusawa, M. Hrab, V. Gailus-Durner, H. Fuchs, TM Conlon, R.S.J. Sarker, Yildirim, Gerald Burgstaller, Lisa Merthan, J. Dorer, de Angelis
Publikováno v:
A29. DESTROYING THE LUNG WITH A PUFF.
Autor:
Michael J. Hanley, Meera Tugnait, Karthik Venkatakrishnan, David Kerstein, Daryl Sonnichsen, Narayana I. Narasimhan, David J. Dorer, Neeraj Gupta
Publikováno v:
Clinical Pharmacology in Drug Development
Brigatinib, a next‐generation anaplastic lymphoma kinase (ALK) inhibitor, received accelerated approval in the United States for the treatment of patients with metastatic ALK+ non–small‐cell lung cancer who have progressed on or are intolerant
Autor:
Glen J. Weiss, Rafael Rosell, Kathryn A. Gold, Meera Tugnait, Scott N. Gettinger, Timothy P. Clackson, David Kerstein, Frank G. Haluska, Lyudmila Bazhenova, Narayana I. Narasimhan, D.R. Camidge, Ravi Salgia, Corey J. Langer, Victor M. Rivera, Alice T. Shaw, David J. Dorer
Publikováno v:
The Lancet Oncology. 17:1683-1696
Summary Background Anaplastic lymphoma kinase ( ALK ) gene rearrangements are oncogenic drivers of non-small-cell lung cancer (NSCLC). Brigatinib (AP26113) is an investigational ALK inhibitor with potent preclinical activity against ALK mutants resis
Autor:
Michele Baccarani, Ronald Knickerbocker, David J. Dorer, Andreas Hochhaus, Moshe Talpaz, Frank G. Haluska, Jorge E. Cortes
Publikováno v:
Leukemia Research. 48:84-91
Background: Ponatinib is an approved potent pan–BCR-ABL tyrosine kinase inhibitor (TKI) with proven efficacy in refractory Ph+ leukemia, particularly CP-CML. Previous analyses suggest significant association between ponatinib dose intensity and adv
Autor:
Alexander C. Bunck, Ralf A. Claus, Ha-Yeun Chung, Daniel C Hupe, Gordon P. Otto, Marcel Sprenger, Clemens L. Bockmeyer, Markus H. Gräler, Michael J. Dorer, Hans-Peter Deigner
Publikováno v:
Molecular Medicine, Vol 22, Iss 1, Pp 412-423 (2016)
The pathophysiology of sepsis involves activation of acid sphingomyelinase (SMPD1) with subsequent generation of the bioactive mediator ceramide. We herein evaluate the hypothesis that the enzyme exerts biological effects in endothelial stress respon
Autor:
Jeffrey Davis, Daryl Sonnichsen, David J. Dorer, Narayana I. Narasimhan, Christopher D. Turner
Publikováno v:
Clinical Pharmacology in Drug Development. 4:354-360
Ponatinib, an oral tyrosine kinase inhibitor with significant activity in heavily pretreated patients with chronic myeloid leukemia, is a CYP3A4 substrate. This open-label, nonrandomized, fixed-order crossover study evaluated the effect of multiple o
Publikováno v:
Journal of Clinical Pharmacy and Therapeutics
What is known and objective Ponatinib is a potent oral tyrosine kinase inhibitor with activity against BCR-ABL, the primary driver of chronic myeloid leukaemia and Philadelphia chromosome–positive acute lymphoblastic leukaemia. This single-centre,
Publikováno v:
The Journal of Clinical Pharmacology. 53:974-981
Ponatinib is a BCR-ABL tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia in patients resistant or intolerant to prior TKIs. In vitro studies sugges